Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas

Abstract

Telomerase activation through induction of its catalytic component telomerase reverse transcriptase (TERT) expression is essential for malignant transformation. TERT promoter mutations namely C228T and C250T that stimulate TERT transcription and telomerase activation have recently been identified in many human malignancies. We thus determined these mutations and their biological and clinical implications in thyroid carcinomas in the present study. The TERT promoter was sequenced in 10 thyroid cancer cell lines and 144 tumors from 20 patients with anaplastic thyroid carcinoma (ATC), 51 with papillary thyroid carcinoma (PTC), 36 with follicular thyroid carcinoma (FTC), and 37 with medullary thyroid carcinoma (MTC). We identified C228T or C250T mutation in 6/8 of ATC cell lines, as well as in tumor tissue from 10/20, 13/51, 8/36 and 0/37 patients with ATC, PTC, FTC and MTC, respectively. In PTC patients, these mutations were exclusively present in the group with age >45 years (P<0.0001), and highly correlated shorter telomeres (P<0.0001) and distant metastasis (P=0.028). The previous radioactivity exposure did not induce the mutation. The presence of C228T or C250T was an independent predictor associated with shorter disease-related survival (DRS) in the entire cohort (P<0.0001), as well as among patients >45 years (P=0.021). ATC patients carrying the mutation survived shorter than those without mutations, although not statistically significant (P=0.129). The TERT promoter mutation was associated with overall survival (P=0.038) and DRS (P=0.058) of FTC patients. Taken together, age- and shorter telomere-dependent TERT promoter mutations occur frequently in follicular cell-derived thyroid carcinoma (ATC, PTC and FTC) but not in parafollicular cell-originated MTC, and may serve as a marker for aggressive disease and poor outcome.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Xing M . Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13: 184–199.

    Article  CAS  Google Scholar 

  2. Hanahan D, Weinberg RA . The hallmarks of cancer. Cell 2000; 100: 57–70.

    Article  CAS  Google Scholar 

  3. Pacini F, Cantara S, Capezzone M, Marchisotta S . Telomerase and the endocrine system. Nat Rev Endocrinol 2011; 7: 420–430.

    Article  CAS  Google Scholar 

  4. Blackburn EH, Greider CW, Szostak JW . Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006; 12: 1133–1138.

    Article  CAS  Google Scholar 

  5. Cong YS, Wright WE, Shay JW . Human telomerase and its regulation. Microbiol Mol Biol Rev 2002; 66: 407–425.

    Article  CAS  Google Scholar 

  6. Shay JW, Bacchetti S . A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787–791.

    Article  CAS  Google Scholar 

  7. Daniel M, Peek GW, Tollefsbol TO . Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012; 498: 135–146.

    Article  CAS  Google Scholar 

  8. Asaad NY, Abd El-Wahed MM, Mohammed AG . Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma: diagnostic and prognostic role. J Egypt Natl Canc Inst 2006; 18: 8–16.

    PubMed  Google Scholar 

  9. Saji M, Xydas S, Westra WH, Liang CK, Clark DP, Udelsman R et al. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res 1999; 5: 1483–1489.

    CAS  PubMed  Google Scholar 

  10. Straight AM, Patel A, Fenton C, Dinauer C, Tuttle RM, Francis GL . Thyroid carcinomas that express telomerase follow a more aggressive clinical course in children and adolescents. J Endocrinol Invest 2002; 25: 302–308.

    Article  CAS  Google Scholar 

  11. Wang Y, Kowalski J, Tsai HL, Marik R, Prasad N, Somervell H et al. Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. Thyroid 2008; 18: 1055–1063.

    Article  CAS  Google Scholar 

  12. Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA, Sukumar S . Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 1997; 57: 2144–2147.

    CAS  PubMed  Google Scholar 

  13. Lerma E, Mora J . Telomerase activity in ‘suspicious’ thyroid cytology. Cancer 2005; 105: 492–497.

    Article  Google Scholar 

  14. Kammori M, Nakamura K, Hashimoto M, Ogawa T, Kaminishi M, Takubo K . Clinical application of human telomerase reverse transcriptase gene expression in thyroid follicular tumors by fine-needle aspirations using in situ hybridization. Int J Oncol 2003; 22: 985–991.

    CAS  PubMed  Google Scholar 

  15. Guerra LN, Miler EA, Moiguer S, Karner M, Orlandi AM, Fideleff H et al. Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma. Clin Chim Acta 2006; 370: 180–184.

    Article  CAS  Google Scholar 

  16. Aogi K, Kitahara K, Buley I, Backdahl M, Tahara H, Sugino T et al. Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. Clin Cancer Res 1998; 4: 1965–1970.

    CAS  PubMed  Google Scholar 

  17. Bornstein-Quevedo L, Garcia-Hernandez ML, Camacho-Arroyo I, Herrera MF, Angeles AA, Trevino OG et al. Telomerase activity in well-differentiated papillary thyroid carcinoma correlates with advanced clinical stage of the disease. Endocr Pathol 2003; 14: 213–219.

    CAS  PubMed  Google Scholar 

  18. Cheng AJ, Lin JD, Chang T, Wang TC . Telomerase activity in benign and malignant human thyroid tissues. Br J Cancer 1998; 77: 2177–2180.

    Article  CAS  Google Scholar 

  19. Hoang-Vu C, Boltze C, Gimm O, Poremba C, Dockhorn-Dworniczak B, Kohrle J et al. Expression of telomerase genes in thyroid carcinoma. Int J Oncol 2002; 21: 265–272.

    CAS  PubMed  Google Scholar 

  20. Brousset P, Chaouche N, Leprat F, Branet-Brousset F, Trouette H, Zenou RC et al. Telomerase activity in human thyroid carcinomas originating from the follicular cells. J Clin Endocrinol Metab 1997; 82: 4214–4216.

    CAS  PubMed  Google Scholar 

  21. Foukakis T, Gusnanto A, Au AY, Hoog A, Lui WO, Larsson C et al. A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr Relat Cancer 2007; 14: 381–391.

    Article  CAS  Google Scholar 

  22. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959–961.

    Article  CAS  Google Scholar 

  23. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA . Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957–959.

    Article  CAS  Google Scholar 

  24. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr. et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110: 6021–6026.

    Article  CAS  Google Scholar 

  25. Tallet A, Nault J-C, Renier A, Hysi I, Galateau-Sallé F, Cazes A et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014; 33: 3748–3752.

    Article  CAS  Google Scholar 

  26. Dinets A, Hulchiy M, Sofiadis A, Ghaderi M, Hoog A, Larsson C et al. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma. Eur J Endocrinol 2012; 166: 1049–1060.

    Article  CAS  Google Scholar 

  27. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013; 20: 603–610.

    Article  Google Scholar 

  28. Liu Z, Li Q, Li K, Chen L, Li W, Hou M et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 2013; 32: 4203–4213.

    Article  CAS  Google Scholar 

  29. Park JI, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009; 460: 66–72.

    Article  CAS  Google Scholar 

  30. Cao Y, Li H, Deb S, Liu JP . TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 2002; 21: 3130–3138.

    Article  CAS  Google Scholar 

  31. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 2002; 99: 12606–12611.

    Article  CAS  Google Scholar 

  32. Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004; 22: 1807–1814.

    Article  CAS  Google Scholar 

  33. Domont J, Pawlik TM, Boige V, Rose M, Weber JC, Hoff PM et al. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol 2005; 23: 3086–3093.

    Article  CAS  Google Scholar 

  34. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS . Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 2004; 22: 3790–3797.

    Article  CAS  Google Scholar 

  35. Sputova K, Garbe JC, Pelissier FA, Chang E, Stampfer MR, Labarge MA . Aging phenotypes in cultured normal human mammary epithelial cells are correlated with decreased telomerase activity independent of telomere length. Genome Integr 2013; 4: 4.

    Article  CAS  Google Scholar 

  36. Cawthon RM . Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Drs N-E Heldin (Uppsala University, Sweden), and BG Robinson and Mr. E Wennerberg (University of Sydney, Australia) for cell lines. The study was funded by grants from the Swedish Cancer Society, the Swedish Research Council, Cancer Society in Stockholm, the Stockholm County Council and Karolinska Institutet. Dr M Hulchiy (Kyiv CIty Teaching Endocrinological Center, Ukraine) for help with retrieval of Ukraine PTC tissue samples.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to C Larsson or D Xu.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Liu, T., Wang, N., Cao, J. et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33, 4978–4984 (2014). https://doi.org/10.1038/onc.2013.446

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.446

Keywords

  • TERT promoter mutation
  • telomere shortening
  • telomerase
  • thyroid cancer

This article is cited by

Search

Quick links